Asia-Pacific Drug Delivery Devices Market, By Product Type (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Pulmonary Drug Delivery, Transmucosal Drug Delivery, and Implantable Drug Delivery), End User (Hospitals, Home Healthcare, Clinics, Community Healthcare and Others), Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacy) - Industry Trends and Forecast to 2031.
Asia-Pacific Drug Delivery Devices Market Analysis and Size
The Asia-Pacific drug delivery devices market is experiencing significant growth, driven by the rising prevalence of chronic disease and non-chronic disease, growth in the development of biologics drugs devices, and increasing awareness about diagnosis and treatment. The market is characterized by the presence of a large number of players offering a wide range of diagnostic devices tailored to meet the diverse needs of healthcare providers in the region.
Data Bridge Market Research analyzes that the Asia-Pacific drug delivery devices market is growing with a CAGR of 9.9% in the forecast period of 2024 to 2031 and is expected to reach USD 669.66 billion by 2031 from USD 320.82 billion in 2023.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Product Type (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Pulmonary Drug Delivery, Transmucosal Drug Delivery, and Implantable Drug Delivery), End User (Hospitals, Home Healthcare, Clinics, Community Healthcare and Others), Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacy)
|
|
Countries Covered
|
Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, and rest of Asia-Pacific
|
|
Market Players Covered
|
Johnson & Johnson Services, Inc., Novartis AG, F.Hoffmann-La Roche Ltd, Bayer AG, Pfizer Inc., 3M, AbbVie Inc., Amgen Inc., BD, Elcam Medical, Gerresheimer AG, GSK plc., Insulet Corporation, Medmix, Merck & Co., Inc., OraSure Technologies Inc., Sanofi, SMC Ltd., and West Pharmaceutical Services Inc. among others
|
Market Definition
Drug delivery devices are medical devices designed to deliver medications to the body in a controlled and targeted manner, enhancing their efficacy, safety, and patient compliance. These devices can be external, such as inhalers, injectors, and pumps, or internal such as implantable devices, and are used to administer a wide range of medications, including small molecules, biologics, and vaccines. They can modify the release rate, bioavailability, and absorption of drugs, as well as provide real-time monitoring and feedback to patients and healthcare providers. Drug delivery devices play a crucial role in optimizing treatment outcomes and improving patient quality of life for various diseases and conditions, including chronic conditions, infectious diseases, and cancer.
Asia-Pacific Drug Delivery Devices Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Rising Prevalence of Chronic Disease and Non-Chronic Disease
The prevalence of diseases and conditions such as Cardiovascular Diseases (CVDs), asthma, cancer, neurological disorders, stroke, diabetes, and respiratory diseases has increased significantly over some time. Mentioned below are some of the important statistics related to some of the chronic diseases. The rising prevalence of chronic and non-chronic diseases significantly influences the growth of the drug delivery devices market. Chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders are becoming more widespread, necessitating long-term treatment plans that require efficient and reliable drug delivery device methods.
- Growth in the Development of Biologics Drugs Devices
Biologics is considered one of the fastest-growing segments in the pharmaceutical market. Development and manufacturing of biologics for both branded and generic drugs is becoming increasingly competitive with the presence of players. Biologics are generally administered through injections in the arms, legs or abdomen. For instance, Cimzia, Cosentyx, Enbrel, and Humira among others.
Opportunity
- Rising Acceptance of Self-Administering Drug Devices
Self-administration of drugs by the patients is expected to provide significant growth opportunities for drug delivery players focusing on the development of innovative and new devices. Major factors contributing to this are growing elderly population, as aged population forms large consumer base for homecare drug delivery devices. Pharmaceutical companies are focusing on the development of patient-friendly therapies and self-administered drug-device combination products. With the increasing acceptance of self-administration, the need for application-specific injection, inhalation, topical, and transdermal drug products is also increasing.
Restraint/Challenge
- Side Effects of Drug Delivery Systems
Adverse reactions to drug delivery systems can lead to a decrease in patient compliance, which can result in decreased demand for the device. This can negatively impact the sales and revenue of the device manufacturer. Side effects can raise concerns about patient safety, leading to increased scrutiny and regulation from regulatory agencies. This can lead to delays in product launches, additional testing requirements, and increased costs for device manufacturers. Moreover, side effects can lead to device rejection by patients, resulting in a decrease in demand for the device. This can be particularly problematic for devices that require long-term use, such as implantable devices.
Recent Developments
- In August 2023, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. submitted the supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking sanction of DARZALEX in combination with Kyprolis and dexamethasone for relapsed/refractory multiple myeloma. If approved this will increase the product portfolio and also revenue generation of the company
- In January 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced that EC has given the grant to market Erleada which is used to treat metastatic hormone-sensitive prostate cancer (mHSPC) in combination with Androgen Deprivation Therapy (ADT). This will increase their market presence which will further increase the revenue generation
- In December 2020, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. announced the EC approval of SPRAVATO nasal spray, which will enhance their product portfolio which will further increase the revenue
Asia-Pacific Drug Delivery Devices Market Scope
The Asia-Pacific drug delivery devices market is segmented into three notable segments based on product type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product Type
- Oral Drug Delivery
- Injectable Drug Delivery
- Topical Drug Delivery
- Ophthalmic Drug Delivery
- Nasal Drug Delivery
- Pulmonary Drug Delivery
- Transmucosal Drug Delivery
- Implantable Drug Delivery
On the basis of product type, the Asia-Pacific drug delivery devices market is segmented into injectable drug delivery formulations, injectable drug delivery, topical drug delivery, ophthalmic drug delivery, nasal drug delivery, pulmonary drug delivery, transmucosal drug delivery, and implantable drug delivery.
End User
- Hospitals
- Home Healthcare
- Clinics
- Community Healthcare
- Others
On the basis of end user, the Asia-Pacific drug delivery devices market is segmented into hospitals, home healthcare, clinics, community healthcare and others.
Distribution Channel
- Direct Tenders
- Hospital Pharmacies
- Pharmacy Stores
- Online Pharmacy
On the basis of distribution channel, the Asia-Pacific drug delivery devices market is segmented into direct tenders, hospital pharmacies, pharmacy stores, and online pharmacy.
Asia-Pacific Drug Delivery Devices Market Regional Analysis/Insights
Asia-Pacific drug delivery devices market is analyzed, and market size insights and trends are provided by based on product type, end user, and distribution channel as referenced above.
The countries covered in this market report are Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, and rest of Asia-Pacific.
China is expected to dominate in the Asia-Pacific market due to its rapidly expanding healthcare sector, substantial investments in medical technology innovation, and a large and increasingly affluent population driving demand for advanced healthcare solutions.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Drug Delivery Devices Market Share Analysis
The Asia-Pacific drug delivery devices market is segmented into three notable segments based on product type, end user, and distribution channel.
The Asia-Pacific drug delivery devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Asia-Pacific drug delivery devices market.
Some of the major players operating in the the Asia-Pacific drug delivery devices market are Johnson & Johnson Services, Inc., Novartis AG, F.Hoffmann-La Roche Ltd, Bayer AG, Pfizer Inc., 3M, AbbVie Inc., Amgen Inc., BD, Elcam Medical, Gerresheimer AG, GSK plc., Insulet Corporation, Medmix, Merck & Co., Inc., OraSure Technologies Inc., Sanofi, SMC Ltd., and West Pharmaceutical Services Inc. among others.
SKU-